妊娠期接种破伤风、白喉、无细胞百日咳(Tdap)疫苗的安全性
该队列研究纳入Kaiser Permanente南加州(KPSC)16,606对妊娠成员,评估妊娠第27周及以后接种Tdap疫苗的安全性。主要终点子痫前期/子痫和宫内感染的调整相对风险(aRR)分别为1.38和1.28,但均未超过预设的2倍阈值,且与背景趋势一致;未观察到小于胎龄儿或早产风险增加。结论支持妊娠期接种Tdap疫苗的安全性。
要点
- 妊娠第27周及以后接种Tdap疫苗与子痫前期/子痫(aRR=1.38)和宫内感染(aRR=1.28)风险升高相关,但未超过预设的2倍非劣效阈值。
- 未观察到小于胎龄儿(aRR=1.04)或早产(aRR=0.71)风险增加。
- 其他次要终点(包括胎儿生长不良、未足月胎膜早破、死产/胎儿死亡、胎盘早剥、分娩住院输血和新生儿死亡)均未显示风险增加。
核心结论
- 妊娠第27周及以后接种Tdap疫苗与预设的母体和婴儿结局风险增加无关,支持妊娠期接种Tdap疫苗的安全性。
研究设计与样本
- 在Kaiser Permanente南加州(KPSC)妊娠成员中进行的队列研究。
- 暴露组为2018年1月至2019年1月期间妊娠第27周及以后接种Tdap疫苗的女性;未暴露组为2012年1月至2014年12月期间妊娠且整个孕期未接种任何Tdap疫苗的匹配女性。
- 分析共纳入16,606对Tdap接种者和未暴露孕妇。
- 通过自动化数据和电子健康记录审查收集母体和婴儿特征及预设终点。
- 采用泊松回归估计未调整和调整相对风险(aRR)及置信区间(CI)。
主要发现
- 主要终点:子痫前期/子痫的aRR为1.38(98.75% CI:1.21-1.58),宫内感染的aRR为1.28(98.75% CI:1.12-1.47)。
- 上述风险增加与KPSC自2011年以来所有孕妇中这些诊断的背景上升趋势一致,且两个aRR的98.75% CI上限均未超过预设阈值2。
- 未观察到小于胎龄儿风险增加(aRR=1.04,98.75% CI:0.94-1.16)或早产风险增加(aRR=0.71,98.75% CI:0.64-0.78)。
- 次要终点(包括胎儿生长不良、未足月胎膜早破、死产/胎儿死亡、胎盘早剥、分娩住院输血和新生儿死亡)均未观察到风险增加的证据。
关键数值与推荐
- 主要终点非劣效性检验的预设阈值为2倍增加。
- 子痫前期/子痫的aRR为1.38(98.75% CI:1.21-1.58)。
- 宫内感染的aRR为1.28(98.75% CI:1.12-1.47)。
- 小于胎龄儿的aRR为1.04(98.75% CI:0.94-1.16)。
- 早产的aRR为0.71(98.75% CI:0.64-0.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to evaluate the safety of prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination. This cohort study was conducted among pregnant members at Kaiser Permanente Southern California (KPSC). The exposed cohort consisted of women who received Tdap vaccine on or after the 27th week of pregnancy between January 2018 and January 2019. The unexposed cohort consisted of matched women who were pregnant between January 2012 and December 2014 and were not vaccinated with any Tdap vaccine throughout their pregnancy. Maternal and infant characteristics and pre-specified endpoints were collected through automated data and review of the electronic health records. Unadjusted and adjusted relative risks (aRRs) with confidence intervals (CIs) were estimated by Poisson regression. Non-inferiority testing (i.e., to rule out a two-fold increase) was conducted for primary endpoints with adjustment for multiplicity. Superiority testing was conducted without multiplicity adjustment for secondary endpoints. The analysis consisted of 16,606 pairs of Tdap recipients and unexposed pregnant women. For the primary endpoints, the aRR for preeclampsia/eclampsia was 1.38 (98.75% CI:1.21-1.58) and the aRR for intrauterine infection was 1.28 (98.75% CI:1.12-1.47). These increases were consistent with the background increasing trend of these diagnoses among all pregnant women at KPSC since 2011, and the upper limit of the 98.75% CI of both aRRs did not exceed the pre-specified threshold of 2. No increased risks of small for gestational age (aRR = 1.04, 98.75% CI:0.94-1.16) or preterm delivery (aRR = 0.71, 98.75% CI:0.64-0.78) were observed. No evidence of increased risks for secondary endpoints, including poor fetal growth, preterm pre-labor rupture of membranes, stillbirth/fetal death, placental abruption, transfusion during delivery hospitalization, and neonatal death, was observed. Prenatal Tdap vaccination after the 27th week of pregnancy was not associated with increased risks of pre-specified maternal and infant outcomes, supporting the safety of Tdap vaccination during pregnancy.
引用
- Tseng HF, Sy LS, Ackerson BK, et al. Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy. Vaccine. 2022. PMID: 35717267. doi:10.1016/j.vaccine.2022.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。